Where I see patients (3)
My reviews
4.8
Selected research
-
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research
-
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
Late-onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma.
American journal of medical genetics. Part A
Clinical trials
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor P...
Will be defined as the proportion of participants randomized to that arm whose status is stable disease (SD) or better (complete response (CR), partial response (PR)). The observed ORR will be compared to the respective null (inef...
Recruiting
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous R...
ORR is defined as the percentage of participants who achieve a confirmed complete response ([CR]; disappearance of all target lesions) or partial response ([PR]: ≥30% decrease in the sum of diameters of target lesions) as assessed...
Recruiting
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Adv...
Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline
Recruiting
Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in ...
A dose limiting toxicity (DLT) will be defined as any predetermined adverse events occurring during Cycle 1 when association to therapy that is part of this study is related or possibly related
Recruiting
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Hom...
ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. ...
Recruiting